|Bid||24.90 x 1100|
|Ask||25.83 x 800|
|Day's Range||24.85 - 25.40|
|52 Week Range||24.81 - 58.69|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
New Mountain Vantage Advisers disclosed an interest of 2,979,665 shares of enterprise IT-services firm Virtusa. New Enterprise Associates revealed an initial position in Nkarta, an oncology biotech firm, of 2,902,115 shares.
Nkarta Inc. said late Tuesday it raised $289.8 million in its recent public offering after underwriters exercised all their options for shares to cover overallotments. On Friday, the biotech company priced 16.1 million shares at $18 and offered underwriters options for an additional 2.1 million, but on the first day of trading, shares rocketed to a high of $58.69. In the meantime, shares have settled a bit, shedding 20% on Monday, and closing down 6.4% at $36.05 on Tuesday, for market cap of $1.1 billion.
SOUTH SAN FRANCISCO, Calif., July 14, 2020 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies.